evaluated for their in vitro DHFR inhibition, antimicrobial, and antitumor activities. Compounds 28 and 61 proved to be active DHFR inhibitors with IC50 0.02 and 0.01μM, respectively. Molecular modeling studies concluded that recognition with the key amino acid Phe34 is essential for binding and hence DHFR inhibition. Compounds 34, 56 and 66 showed broad spectrum antimicrobial activity comparable to Gentamicin
设计,合成并评估了一系列新的2,3,6-取代的
喹唑啉-4-酮系列化合物,它们的体外DHFR抑制,抗菌和抗肿瘤活性均得到了评估。化合物28和61被证明是活性DHFR
抑制剂,IC50分别为0.02和0.01μM。分子模型研究得出结论,关键
氨基酸Phe34的识别对于结合并因此抑制DHFR是必不可少的。化合物34、56和66显示出与
庆大霉素和
环丙沙星相当的广谱抗菌活性。化合物40和64对几种肿瘤
细胞系表现出广谱抗肿瘤活性,并被证明比5-FU活性高10倍,GI50 MG-MID值分别为2.2和2.4μM。